| 臺大學術典藏 |
2020-05-26T09:27:11Z |
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
|
Wu Y.-L;Park K;Soo R.A;Sun Y;Tyroller K;Wages D;Ely G;Chih-Hsin Yang;Mok T.; Wu Y.-L; Park K; Soo R.A; Sun Y; Tyroller K; Wages D; Ely G; CHIH-HSIN YANG; Mok T. |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:59Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
CHIH-HSIN YANG; Kang J.H; Mok T; Ahn M.-J; Srimuninnimit V; Lin C.-C; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma
|
Park K.;Close S;Garrus J.E;Payumo F;Komarnitsky P;Han M;Chang G.-C;Chih-Hsin Yang;Tan E.-H;Su W.-C;Geater S.L;Mok T.S.K; Mok T.S.K; Geater S.L; Su W.-C; Tan E.-H; CHIH-HSIN YANG; Chang G.-C; Han M; Komarnitsky P; Payumo F; Garrus J.E; Close S; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial
|
Lux-Lung 5 Investigators;Serwatowski P;Kazarnowicz A;Jaskiewicz P;Palomino O.L.M;Pantigoso W.R;Barreda R.L.A;S?nchez J.F.S;Gans S;Herder G;Dingemans A.-M;Stigt J;Aerts J;Baca O.P;Luna G.A;Perez J.L.G;Delgado F.G;Cruciani G;Ceresoli G.L;Platania M;Milandri C;Gridelli C;Bearz A;Bidoli P;Migliorino M.R;Stemmer S;Gottfried M;Onn A;Nagarkar R.V;Dadhich H;Sharma L;Venkatesan S;Jain M;Prabhash K;Sarosi V;Strausz J;Tehenes S;Mark Z;Wiewrodt R;Dickgreber N;Huber R;Von Pawel J;Laack E;Keilholz U;Faehling M;Wehler T;Thomas M;Coudert B;Rotarski M;Gervais R;Fournel P;Bennouna J;Planchard D;Perol M;Sibilot D.M;Zalcman G;Chouaid C;Cadranel J;Alanko T;Riska H;Zadra C.A;Garicochea B;Zereu M;Lu S;Zhang Y;Huang J;Feng J;Qin S;Cheng Y;Liu X;Wu Y;Lin X;Thropay J;Meza L;Gurtler J;Summers Y;Upadhyay S;Brown E;Talbot T;Toy E;Spicer J;Popat S;Mitra S;Shah R;Polishchuk I;Bondarenko I;Ponomarova O;Popovych O;Vinnyk Y;Hsieh R.-K;Ho C.-L;Huang M.-S;Su W.-C;Tsao T.C.-Y;Chang G.-C;Tsai Y.-H;Chen Y.-M;Hsia T.-C;Yang C.-H;Kim Y.-C;Han J.-Y;Kim J.-H;Park K;Kim S.-W;Kim D.-W;Felip E;Cobo M;Lianes P;Campelo R.G;Camps C;Larriba J.L.G;Garrido P;Ragulin Y;Orlov S;Karaseva N;Lubennikov V;Jassem J;Szczesna A;Huang C;Wang J;Zhou C;Vercauter P;Delval L;Lambrechts M;Galdermans D;Carestia L;Bustin F;Humblet Y;Greil R;Mainwaring P;Crombie C;Underhill C;Parente P;Mclachlan S.-A;Richardet M;Blajman C;Zarba J.J;Recondo G;Martin C.M;Bagnes C;Planchard D;Chand V.K;Wang B;Zhou C;Wiewrodt R;Vinnyk Y;Strausz J;Lu S;Liu X;Kim D.-W;Grossi F;Feng J.-F;De Marinis F;Chouaid C;Chen Y.-M;Bennouna J;Kim J.-H;Park K;Chih-Hsin Yang;Schuler M; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators; Schuler M; CHIH-HSIN YANG; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
|
Mok T; Kim M; Paz-Ares L.; Paz-Ares L.;Kim M;Mok T;Chih-Hsin Yang;Boyer M;O'Byrne K;Hirsh V;Zhang L;Tan E.-H;Park K; Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non-small-cell lung cancer
|
Chih-Hsin Yang;Lin C.-B;Lee K.-H;Cho E.K;Park K;Tanaka H;Ichinose Y;Yamada K;Kato T;Kaneda H;Hayashi H;Nakagawa K;Yoh K;Hida T;Oshita F;Yoshioka H;Hara K;Asato T;Kubota K; Kubota K; Asato T; Hara K; Yoshioka H; Oshita F; Hida T; Yoh K; Nakagawa K; Hayashi H; Kaneda H; Kato T; Yamada K; Ichinose Y; Tanaka H; Park K; Cho E.K; Lee K.-H; Lin C.-B; CHIH-HSIN YANG |
